Key Highlights
- French pharmaceutical company Servier will purchase Day One Biopharmaceuticals (DAWN) at $21.50 per share in a transaction valued at approximately $2.5 billion
- Shareholders will receive a ~68% premium over Thursday’s closing price and an 86% premium compared to the 30-day volume-weighted average
- Premarket trading on March 6, 2026 showed DAWN shares climbing ~66% after the acquisition announcement
- The company’s board gave unanimous approval for the transaction and advised shareholders to accept the tender offer
- Deal completion is anticipated during Q2 2026, contingent upon regulatory approval and shareholder participation
French pharmaceutical company Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals (DAWN) through an all-cash transaction totaling approximately $2.5 billion. Following the announcement on Friday, March 6, DAWN shares experienced a premarket surge of roughly 66%.
https://x.com/FenwickWest/status/2029944210065969265?s=20
Servier will acquire each outstanding share of Day One common stock for $21.50. This acquisition price represents a 68% markup over Thursday’s closing valuation and an 86% increase compared to the 30-day volume-weighted average share price.
Day One Biopharmaceuticals, Inc., DAWN
The transaction proceeds without any financing contingency, eliminating a typical hurdle that sometimes prevents deals from completing. The parties anticipate closing during the second quarter of 2026, dependent on receiving U.S. antitrust approval and acceptance from a majority of DAWN shareholders through the tender process.
Day One’s board conducted a thorough evaluation of the proposal and unanimously determined to advise shareholders to tender their shares. Standard non-solicitation terms govern the agreement, along with an $87.7 million termination fee payable under specific circumstances if the transaction fails to close.
Market observers had some advance warning of potential corporate activity. DAWN shares experienced upward movement on Wednesday following media reports suggesting takeover interest, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) identified among potential bidders at that time.
Strategic Assets Driving the Acquisition
The primary asset Servier gains through this acquisition is tovorafenib, Day One’s lead therapeutic candidate designed to treat low-grade glioma — a brain tumor classification. This medication addresses an important need within pediatric oncology, the therapeutic area where Day One has concentrated its development efforts.
For Servier, this transaction strengthens its position in rare oncology treatments. The French pharmaceutical organization, which generated €6.9 billion in revenue during fiscal 2024/25, currently allocates nearly 20% of branded product revenue toward research and development activities. Acquiring Day One’s therapeutic portfolio aligns with the company’s strategic priority of expanding its capabilities in targeted cancer medicines.
Transaction Mechanics
The acquisition follows an all-cash tender offer structure, with a subsequent merger step once all requirements are satisfied. Servier’s ability to complete the purchase without arranging additional financing strengthens expectations that the deal will close as planned.
The $87.7 million termination payment provides Day One with financial protection should the transaction fail to reach completion.
Analyst coverage prior to the acquisition announcement included a $17.00 price target with a Buy rating — considerably lower than the $21.50 per share acquisition price Servier agreed to pay.
Day One’s market capitalization before the deal announcement measured approximately $1.35 billion. The $2.5 billion transaction value demonstrates the substantial premium Servier committed to secure access to the company’s drug pipeline.
Day One operates from its Brisbane, California headquarters. Upon completion, the acquisition will transfer complete ownership to Servier, a privately held French pharmaceutical group that markets medicines across more than 130 countries worldwide.
